Peptides and combination of peptides for use in immunotherapy against various tumors
A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
1. A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal cancer (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia/prostate cancer (BPH, PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder adenocarcinoma and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and/or uterine cancer (UEC), comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt and an adjuvant, wherein said peptide consists of the amino acid sequence of ILAEEPIYI (SEQ ID NO: 81), thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
2. The method of claim 1 , wherein the T cell response is a cytotoxic T cell response.
3. The method of claim 1 , wherein the cancer is HCC.
4. The method of claim 1 , wherein the cancer is CRC.
5. The method of claim 1 , wherein the cancer is GB.
6. The method of claim 1 , wherein the cancer is GC.
7. The method of claim 1 , wherein the cancer is esophageal cancer.
8. The method of claim 1 , wherein the cancer is NSCLC.
9. The method of claim 1 , wherein the cancer is PC.
10. The method of claim 1 , wherein the cancer is RCC.
11. The method of claim 1 , wherein the cancer is BPH PCA.
12. The method of claim 1 , wherein the cancer is OC.
13. The method of claim 1 , wherein the cancer is melanoma.
14. The method of claim 1 , wherein the cancer is BRCA.
15. The method of claim 1 , wherein the cancer is CLL.
16. The method of claim 1 , wherein the cancer is NHL.
17. The method of claim 1 , wherein the cancer is AML.
18. The method of claim 1 , wherein the cancer is UBC.
19. The method of claim 1 , wherein the cancer is UEC.
20. The method of claim 1 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.